Corpus overview


MeSH Disease

Dysgeusia (15)

Disease (7)

Fever (7)

Cough (7)

Infections (7)

Human Phenotype

Anosmia (12)

Fever (7)

Cough (7)

Myalgia (4)

Diarrhea (3)


    displaying 1 - 10 records in total 15
    records per page

    Effects of COVID-19 on the Gut and the Liver - A Case Series of 711 Patients in New York City

    Authors: Sher Nazir Baig, MD; Fuad Abaleka, MD; Stephanie Herrera, MD; Mina Daniel, MD; Bisrat Nigusse, MD; Thu M Vu, MD; Tigist Gemechu, MD; George Abdelsayed, MD, FACG

    doi:10.21203/ Date: 2020-08-06 Source: ResearchSquare

    Background As the COVID-19 epidemic is wreaking havoc with a staggering number of infections MESHD and fatalities worldwide, digestive symptoms are increasingly coming to the limelight. However, the data on the extent of gut and liver involvement has been variable and somewhat conflicting.Methods We identified 711 adults TRANS who had tested positive for COVID-19 at Richmond University Medical Center in New York between March 13 and May 13, 2020. We analyzed their clinical and laboratory data from electronic medical records.Results The average age TRANS of the patients was 60.5 years; 55% were men. 27.1% reported a gastrointestinal (GI) symptom and 56.9% had at least one abnormal liver enzyme. The most common was diarrhea MESHD diarrhea HP with a frequency of 17.3% followed by nausea MESHD nausea HP 16.2% and vomiting MESHD vomiting HP/ anorexia MESHD anorexia HP 13.7%. Abdominal pain MESHD Abdominal pain HP 5.6%, dysgeusia MESHD 3.2%, and GI bleeding 2.2% was the least common. Symptoms were mostly mild and lasted 3-5 days. The liver function was deranged in more than half of the patients. AST alone was elevated in 16.6%, both AST/ALT 15.7%, alkaline phosphatase 23%, and bilirubin 10%. Potential confounders were rare but included preexisting liver disease MESHD and hepatotoxic medications. Prothrombin time (PT) was mildly elevated in 13.4%. The lipase was elevated in 2.4% without upper abdominal pain MESHD abdominal pain HP. In 75%-90% of cases, liver test abnormalities were mild (1.5-3 x normal). Overall, 86.6% of patients were admitted primarily with respiratory failure HP and 28.5% died of their illness.Conclusions 27% of COVID-19 patients experienced a digestive disturbance and >55% showed a predominantly mild degree of liver dysfunction and cholestasis MESHD cholestasis HP.

    Hiccups MESHD and Psychosis HP: Two atypical presentations of COVID -19

    Authors: Teresa Alvarez-Cisneros; Aldo Lara-Reyes; Stephanie Sansón-Tinoco

    doi:10.21203/ Date: 2020-07-23 Source: ResearchSquare

    The WHO defines a possible case of COVID-19 as a person experiencing fever MESHD fever HP, cough MESHD cough HP, shortness of breath and neurological signs including anosmia HP, ageusia MESHD or dysgeusia MESHD. However, experiences from hospitals all over the world have shown that presentations vary widely. In our emergency MESHD department in a private hospital in Mexico City, we received two patients with very different symptoms on the same shift. Two previously healthy men in their 40 s presented, one with 3 days of hiccups MESHD and the other with a new onset psychotic event.

    Olfactory and gustatory dysfunction in 2019 novel coronavirus: An updated systematic review and meta-analysis

    Authors: Marzieh Esmaeili; Fatemeh Abdi; Gita Shafiee; Hadis Rastad; Hamid Asayesh; Zahra Esmaeili Abdar; Fereshteh Baygi; Mostafa Qorbani

    doi:10.21203/ Date: 2020-07-17 Source: ResearchSquare

    BackgroundEvidence showed that partial or complete loss of smell and taste might be a possible primary symptom of the 2019 novel coronavirus (COVID-19). This study aimed to systematically review and pool all available evidence on the olfactory and gustatory dysfunction in COVID-19 patients. MethodsIn this systematic review, a comprehensive search was carried out systematically through e-databases including PubMed, EMBASE, Scopus, and Web of Science (WoS); that was limited to English-language studies published from 2019 up to 6th May 2020. Afterward, all studies reported the taste and smell dysfunction in the COVID-19 patients were included. The quality of the studies was assessed by the Mixed Methods Appraisal Tool (MMAT). The pooled prevalence SERO of olfactory and gustatory dysfunction was estimated using the random effects meta-analysis method.ResultsAmong 28 eligible included studies in this systematic review, finally, 22 studies met the eligibility criteria and were included in the meta-analysis. According to the random effect meta-analysis, the global pooled prevalence SERO (95% confidence interval) of any olfactory dysfunction, anosmia HP, and hyposmia HP was 55% (40%-70%), 40% (22%-57%), and 40% (20%-61%) respectively. The pooled estimated prevalence SERO of any gustatory dysfunction, ageusia MESHD, and dysgeusia MESHD was 41% (23%-59%), 31% (3%-59%), and 34% (19%-48%) respectively. ConclusionOlfactory and gustatory dysfunction is prevalent among COVID-19 patients. Therefore, olfactory and gustatory dysfunction seems to be part of important symptoms and notify for the diagnosis of COVID-19, especially in the early phase of the infection MESHD.

    Reconstructing the global dynamics of under-ascertained COVID-19 cases and infections MESHD

    Authors: Nick Golding; Timothy W Russell; Sam Abbott; Joel Hellewell; Carl A B Pearson; Kevin van Zandvoort; Christopher I Jarvis; Hamish Gibbs; Yang Liu; Rosalind M Eggo; John W Edmunds; Adam J Kucharski

    doi:10.1101/2020.07.07.20148460 Date: 2020-07-08 Source: medRxiv

    Background: Asymptomatic TRANS or subclinical SARS-CoV-2 infections MESHD are often unreported, which means that confirmed case TRANS counts may not accurately reflect underlying epidemic dynamics. Understanding the level of ascertainment (the ratio of confirmed symptomatic cases to the true number of symptomatic individuals) and undetected epidemic progression is crucial to informing COVID-19 response planning, including the introduction and relaxation of control measures. Estimating case ascertainment over time allows for accurate estimates of specific outcomes such as seroprevalence SERO, which is essential for planning control measures. Methods: Using reported data on COVID-19 cases and fatalities globally, we estimated the proportion of symptomatic cases (i.e. any person with any of fever MESHD fever HP >= to 37.5C, cough MESHD cough HP, shortness of breath, sudden onset of anosmia HP, ageusia MESHD or dysgeusia MESHD illness) that were reported in 210 countries and territories, given those countries had experienced more than ten deaths MESHD. We used published estimates of the case fatality ratio (CFR) as an assumed baseline. We then calculated the ratio of this baseline CFR to an estimated local delay-adjusted CFR to estimate the level of under-ascertainment in a particular location. We then fit a Bayesian Gaussian process model to estimate the temporal pattern of under-ascertainment. Results: We estimate that, during March 2020, the median percentage of symptomatic cases detected across the 84 countries which experienced more than ten deaths MESHD ranged from 2.38% (Bangladesh) to 99.6% (Chile). Across the ten countries with the highest number of total confirmed cases TRANS as of 6th July 2020, we estimated that the peak number of symptomatic cases ranged from 1.4 times (Chile) to 17.8 times (France) larger than reported. Comparing our model with national and regional seroprevalence SERO data where available, we find that our estimates are consistent with observed values. Finally, we estimated seroprevalence SERO for each country. Despite low case detection in some countries, our results that adjust for this still suggest that all countries have had only a small fraction of their populations infected as of July 2020. Conclusions: We found substantial under-ascertainment of symptomatic cases, particularly at the peak of the first wave of the SARS-CoV-2 pandemic, in many countries. Reported case counts will therefore likely underestimate the rate of outbreak growth initially and underestimate the decline in the later stages of an epidemic. Although there was considerable under-reporting in many locations, our estimates were consistent with emerging serological data, suggesting that the proportion of each country's population infected with SARS-CoV-2 worldwide is generally low.

    COVID-19 presenting as anosmia HP and dysgeusia MESHD in New York City emergency MESHD departments, March - April, 2020

    Authors: Tina Z. Wang; Jessica Sell; Don Weiss; Ramona Lall

    doi:10.1101/2020.07.06.20147751 Date: 2020-07-07 Source: medRxiv

    Background: Increasing evidence has been emerging of anosmia HP and dysgeusia MESHD as frequently reported symptoms in COVID-19. Improving our understanding of these presenting symptoms may facilitate the prompt recognition of the disease MESHD in emergency MESHD departments and prevent further transmission TRANS. Methods: We examined a cross-sectional cohort using New York City emergency MESHD department syndromic surveillance data for March and April 2020. Emergency MESHD department visits for anosmia HP and/or dysgeusia MESHD were identified and subsequently matched to the Electronic Clinical Laboratory Reporting System to determine testing results for SARS-CoV-2. Results: Of the 683 patients with anosmia HP and/or dysgeusia MESHD included, SARS-CoV-2 testing was performed for 232 (34%) and 168 (72%) were found to be positive. Median age TRANS of all patients presenting with anosmia HP and/or dysgeusia MESHD symptoms was 38, and 54% were female TRANS. Anosmia HP and/or dysgeusia MESHD was the sole complaint of 158 (23%) patients, of whom 35 were tested for SARS-CoV-2 and 23 (66%) were positive. While the remaining patients presented with at least one other symptom, nearly half of all patients (n=334, 49%) and more than a third of those who tested positive (n=62, 37%) did not have any of the CDC-established symptoms used for screening of COVID-19 such as fever MESHD fever HP, cough MESHD cough HP, shortness of breath, or sore throat. Conclusions and Relevance: Anosmia HP and/or dysgeusia MESHD have been frequent complaints among patients presenting to emergency MESHD departments during the COVID-19 pandemic, and, while only a small proportion of patients ultimately underwent testing for SARS-CoV-19, the majority of patients tested have been positive. Anosmia HP and dysgeusia MESHD likely represent underrecognized symptoms of COVID-19 but may have important future implications in disease MESHD diagnosis and surveillance.


    Authors: Antoni Sisó-Almirall; Belchin Kostov; Minerva Mas-Heredia; Sergi Vilanova-Rotllan; Ethel Sequeira-Aymar; Mireia Sans-Corrales; Elisenda Sant-Arderiu; Laia Cayuelas-Redondo; Angela Martínez-Pérez; Noemí García Plana; August Anguita-Guimet; Jaume Benavent-Àreu

    doi:10.1101/2020.06.18.20134510 Date: 2020-06-20 Source: medRxiv

    Background In addition to the lack of COVID-19 diagnostic tests for the whole Spanish population, the current strategy is to identify the disease MESHD early to limit contagion in the community. Aim To determine clinical factors of a poor prognosis in patients with COVID-19 infection MESHD. Design and Setting Descriptive, observational, retrospective study in three primary healthcare centres with an assigned population of 100,000. Method Examination of the medical records of patients with COVID-19 infections MESHD infections confirmed TRANS confirmed by polymerase chain reaction. Results We included 322 patients (mean age TRANS 56.7 years, 50% female TRANS, 115 (35.7%) aged TRANS [≥] 65 years). The best predictors of ICU admission or death MESHD were greater age TRANS, male TRANS sex (OR=2.99; 95%CI=1.55 to 6.01), fever MESHD fever HP (OR=2.18; 95%CI=1.06 to 4.80), dyspnoea (OR=2.22; 95%CI=1.14 to 4.24), low oxygen saturation (OR=2.94; 95%CI=1.34 to 6.42), auscultatory alterations (OR=2.21; 95%CI=1.00 to 5.29), heart disease MESHD (OR=4.37; 95%CI=1.68 to 11.13), autoimmune disease MESHD (OR=4.03; 95%CI=1.41 to 11.10), diabetes (OR=4.00; 95%CI=1.89 to 8.36), hypertension MESHD hypertension HP (OR=3.92; 95%CI=2.07 to 7.53), bilateral pulmonary infiltrates HP (OR=3.56; 95%CI=1.70 to 7.96), elevated lactate-dehydrogenase (OR=3.02; 95%CI=1.30 to 7.68), elevated C-reactive protein (OR=2.94; 95%CI=1.47 to 5.97), elevated D-dimer (OR=2.66; 95%CI=1.15 to 6.51) and low platelet count (OR=2.41; 95%CI=1.12 to 5.14). Myalgia MESHD Myalgia HP or artralgia (OR=0.28; 95%CI=0.10 to 0.66), dysgeusia MESHD (OR=0.28; 95%CI=0.05 to 0.92) and anosmia HP (OR=0.23; 95%CI=0.04 to 0.75) were protective factors. Conclusion Determining the clinical, biological and radiological characteristics of patients with suspected COVID-19 infection MESHD will be key to early treatment and isolation and the tracing of contacts TRANS.

    Separating the wheat from the chaff – COVID-19 in a German emergency MESHD department: A Case-control study

    Authors: David Fistera; Dirk Pabst; Annalena Härtl; Benedikt Michael Schaarschmidt; Lale Umutlu; Sebastian Dolff; Carola Holzner; Clemens Kill; Joachim Risse

    doi:10.21203/ Date: 2020-06-19 Source: ResearchSquare

    Background: COVID-19 pandemia is a major challenge to worldwide health care systems. Whereas the majority of disease MESHD presents with mild symptoms that can be treated as outpatients, severely ill COVID-19 patients and patients presenting with similar symptoms cross their ways in the Emergency MESHD Department. Especially the variety of symptoms is challenging with primary triage. Are there parameters to distinguish between proven COVID-19 and without before? How can a safe and efficient management of these inpatients be achieved?Methods: We conducted a retrospective analysis of 314 consecutive inpatient patients who presented with possible symptoms of COVID-19 in a German emergency MESHD department between March and April 2020 and were tested with a SARS-Cov-2 nasopharyngeal swab. Clinical parameters, Manchester Triage System categories and lab results were compared between patients with positive and negative test results for SARS-Cov-2. Furthermore, we present the existing COVID-19 workflow model of the university hospital in Essen which proved to be efficient during pandemia.Results: 43 of the 314 patients (13.7%) were tested positive for COVID-19 by SARS-Cov-2 nasopharyngeal swab. We did not find any laboratory parameter to distinguish safely between patients with COVID-19 and those with similar symptoms. Dysgeusia MESHD was the only clinical symptom that was significantly more frequent among COVID-19 patients. Conclusion: Dysgeusia MESHD seems to be a typical symptom for COVID-19, which occurred in 14% of our COVID-19 patients. However, no valid parameters could be found to distinguish clinically between COVID-19 and other diseases MESHD with similar symptoms. Therefore, early testing, a strict isolation policy and proper personal protection are crucial to maintain workflow and safety of patients and ED staff for the months to come.Trial registration: URL: 

    Sudden Onset, Acute Loss of Taste and Smell in Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review

    Authors: Lakshman SAMARANAYAKE; Kausar Fakhruddin; Chamila Panduwawala

    id:10.20944/preprints202006.0198.v1 Date: 2020-06-16 Source:

    Early detection, isolation, and management of COVID-19 patients are crucial to contain the current pandemic. The CDC in USA recently included "sudden loss of taste ( dysgeusia MESHD/ ageusia MESHD) and smell ( anosmia HP/ hyposmia HP)” as symptoms of COVID-19. If these symptoms are reliable forerunner symptoms of COVID-19, then it may facilitate early detection and containment of the disease MESHD. Hence, we systematically evaluated the contemporary evidence on dysgeusia MESHD and anosmia HP as trigger symptoms in COVID-19. Ovid MEDLINE, EBSCO host, and Web of Science databases were searched between December 25, 2019-May 30, 2020.Of the 13 identified records, eight (totaling 11,054 COVID-19 patients), were included, as per the selection criteria. The studies emanated mostly from the European community, as well as China, the USA, and Iran. In total, anosmia HP and dysgeusia MESHD symptoms were present in 74.9 % and 81.3% ambulatory as well as hospitalized, mild-to-severe cases of COVID-19 patients, respectively. The European, US, and Iran data indicate that olfactory, and gustatory symptoms appear prior to general COVID-19 symptoms in a majority of the patients. To our knowledge, this is the first systematic review analyzing the prevalence SERO of chemosensory dysfunction in COVID-19. Further, studies are essential to evaluate their utility as harbingers of COVID-19 onset, and to establish clinical practice guidelines.

    COVID-19-like symptoms and their relation to SARS-CoV-2 epidemic in children TRANS and adults TRANS of an Italian birth cohort

    Authors: Maja Popovic; Chiara Moccia; Elena Isaevska; Giovenale Moirano; Costanza Pizzi; Daniela Zugna; Franca Rusconi; Franco Merletti; Milena Maule; Lorenzo Richiardi

    doi:10.21203/ Date: 2020-06-08 Source: ResearchSquare

    Background Emerging COVID-19 pandemic caused extensive lockdowns in a number of countries, but yet unknown number of cases positive to SARS-CoV-2 escapes surveillance systems. Methods Mothers participating in an Italian NINFEA birth cohort were invited to complete an online questionnaire on COVID-19-like symptoms in the household. We estimated the population prevalence SERO of COVID-19-like symptoms in children TRANS and adults TRANS, assessed their geographical correlation with the cumulative number of COVID-19 cases by province, analysed their clustering within families, and estimated their sensitivity SERO, positive (PPV) and negative predictive values SERO (NPV) for COVID-19 diagnosis in individuals tested for SARS-CoV-2.Results Information was collected on 3184 households, 6133 adults TRANS, and 5751 children TRANS. There was a strong geographical correlation between the population cumulative incidence of COVID-19 and the prevalence SERO of muscle pain MESHD pain HP, fatigue MESHD fatigue HP, low-grade fever HP fever MESHD, and breathing difficulties in adults TRANS (Spearman’s rho ≥0.70). Having at least one family member TRANS with a COVID-19 diagnosis, compared with none tested for SARS-CoV-2, was associated with an increased prevalence SERO ratio of almost all COVID-19-like symptoms in adults TRANS, and only of low-grade fever HP fever MESHD (37-37.5oC; prevalence SERO ratio 5.27; 95% confidence intervals: 2.37 to 11.74) and anosmia HP/ dysgeusia MESHD in children TRANS. Among adults TRANS with COVID-19, fatigue MESHD fatigue HP, muscle pain MESHD pain HP, and fever MESHD fever HP had a sensitivity SERO ≥70%. In individuals tested for SARS-CoV-2, with a 16.6% prevalence SERO of COVID-19, breathing difficulties and nausea MESHD nausea/vomiting HP/ vomiting MESHD had the highest PPVs, with point estimates close to 60%, and with NPVs close to 90%. Among tested Piedmont residents, with a COVID-19 prevalence SERO of 18.5%, breathing difficulties and anosmia HP/disguesia reached PPVs above 80%.Conclusion Geographical prevalence SERO of COVID-19-like symptoms in adults TRANS may inform on local disease MESHD clusters, while certain symptoms in family members TRANS of confirmed COVID-19 cases could help identification of the intra-familial spread of the virus and its further propagation in the community. Low-grade fever HP fever MESHD is frequent in children TRANS with at least one household member with COVID-19 and possibly indicates child TRANS infection MESHD.  


    Authors: Vijairam Selvaraj; Daniel Sacchetti; Arkadiy Finn; Kwame Dapaah-Afriyie

    doi:10.1101/2020.06.03.20112540 Date: 2020-06-05 Source: medRxiv

    To date, there have been reports of neurologic manifestations MESHD in Covid-19 patients including ischemic strokes HP strokes MESHD, Guillain-Barre Syndrome MESHD and anosmia HP. In this case report, we report a patient who presented with dysosmia, dysgeusia MESHD along with monocular peripheral vision loss after being diagnosed with Covid-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.